The impact of coding germline variants on contralateral breast cancer risk and survival
Standard
The impact of coding germline variants on contralateral breast cancer risk and survival. / Morra, Anna; Mavaddat, Nasim; Muranen, Taru A; Ahearn, Thomas U; Allen, Jamie; Andrulis, Irene L; Auvinen, Päivi; Becher, Heiko; Behrens, Sabine; Blomqvist, Carl; Bojesen, Stig E; Bolla, Manjeet K; Brauch, Hiltrud; Camp, Nicola J; Carvalho, Sara; Castelao, Jose E; Cessna, Melissa H; Chang-Claude, Jenny; Chenevix-Trench, Georgia; Czene, Kamila; Decker, Brennan; Dennis, Joe; Dörk, Thilo; Dorling, Leila; Dunning, Alison M; Ekici, Arif B; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Figueroa, Jonine D; Flyger, Henrik; Gago-Dominguez, Manuela; García-Closas, Montserrat; Geurts-Giele, Willemina R R; Giles, Graham G; Guénel, Pascal; Gündert, Melanie; Hahnen, Eric; Hall, Per; Hamann, Ute; Harrington, Patricia A; He, Wei; Heikkilä, Päivi; Hooning, Maartje J; Hoppe, Reiner; Howell, Anthony; Humphreys, Keith; Jakubowska, Anna; Jung, Audrey Y; Keeman, Renske; Kristensen, Vessela N; Lubiński, Jan; Mannermaa, Arto; Manoochehri, Mehdi; Manoukian, Siranoush; Margolin, Sara; Mavroudis, Dimitrios; Milne, Roger L; Mulligan, Anna Marie; Newman, William G; Park-Simon, Tjoung-Won; Peterlongo, Paolo; Pharoah, Paul D P; Rhenius, Valerie; Saloustros, Emmanouil; Sawyer, Elinor J; Schmutzler, Rita K; Shah, Mitul; Spurdle, Amanda B; Tomlinson, Ian; Truong, Thérèse; van Veen, Elke M; Vreeswijk, Maaike P G; Wang, Qin; Wendt, Camilla; Yang, Xiaohong R; Nevanlinna, Heli; Devilee, Peter; Easton, Douglas F; Schmidt, Marjanka K; NBCS Collaborators; KConFab Investigators.
In: AM J HUM GENET, Vol. 110, No. 3, 02.03.2023, p. 475-486.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The impact of coding germline variants on contralateral breast cancer risk and survival
AU - Morra, Anna
AU - Mavaddat, Nasim
AU - Muranen, Taru A
AU - Ahearn, Thomas U
AU - Allen, Jamie
AU - Andrulis, Irene L
AU - Auvinen, Päivi
AU - Becher, Heiko
AU - Behrens, Sabine
AU - Blomqvist, Carl
AU - Bojesen, Stig E
AU - Bolla, Manjeet K
AU - Brauch, Hiltrud
AU - Camp, Nicola J
AU - Carvalho, Sara
AU - Castelao, Jose E
AU - Cessna, Melissa H
AU - Chang-Claude, Jenny
AU - Chenevix-Trench, Georgia
AU - Czene, Kamila
AU - Decker, Brennan
AU - Dennis, Joe
AU - Dörk, Thilo
AU - Dorling, Leila
AU - Dunning, Alison M
AU - Ekici, Arif B
AU - Eriksson, Mikael
AU - Evans, D Gareth
AU - Fasching, Peter A
AU - Figueroa, Jonine D
AU - Flyger, Henrik
AU - Gago-Dominguez, Manuela
AU - García-Closas, Montserrat
AU - Geurts-Giele, Willemina R R
AU - Giles, Graham G
AU - Guénel, Pascal
AU - Gündert, Melanie
AU - Hahnen, Eric
AU - Hall, Per
AU - Hamann, Ute
AU - Harrington, Patricia A
AU - He, Wei
AU - Heikkilä, Päivi
AU - Hooning, Maartje J
AU - Hoppe, Reiner
AU - Howell, Anthony
AU - Humphreys, Keith
AU - Jakubowska, Anna
AU - Jung, Audrey Y
AU - Keeman, Renske
AU - Kristensen, Vessela N
AU - Lubiński, Jan
AU - Mannermaa, Arto
AU - Manoochehri, Mehdi
AU - Manoukian, Siranoush
AU - Margolin, Sara
AU - Mavroudis, Dimitrios
AU - Milne, Roger L
AU - Mulligan, Anna Marie
AU - Newman, William G
AU - Park-Simon, Tjoung-Won
AU - Peterlongo, Paolo
AU - Pharoah, Paul D P
AU - Rhenius, Valerie
AU - Saloustros, Emmanouil
AU - Sawyer, Elinor J
AU - Schmutzler, Rita K
AU - Shah, Mitul
AU - Spurdle, Amanda B
AU - Tomlinson, Ian
AU - Truong, Thérèse
AU - van Veen, Elke M
AU - Vreeswijk, Maaike P G
AU - Wang, Qin
AU - Wendt, Camilla
AU - Yang, Xiaohong R
AU - Nevanlinna, Heli
AU - Devilee, Peter
AU - Easton, Douglas F
AU - Schmidt, Marjanka K
AU - NBCS Collaborators
AU - KConFab Investigators
N1 - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2023/3/2
Y1 - 2023/3/2
N2 - Evidence linking coding germline variants in breast cancer (BC)-susceptibility genes other than BRCA1, BRCA2, and CHEK2 with contralateral breast cancer (CBC) risk and breast cancer-specific survival (BCSS) is scarce. The aim of this study was to assess the association of protein-truncating variants (PTVs) and rare missense variants (MSVs) in nine known (ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53) and 25 suspected BC-susceptibility genes with CBC risk and BCSS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox regression models. Analyses included 34,401 women of European ancestry diagnosed with BC, including 676 CBCs and 3,449 BC deaths; the median follow-up was 10.9 years. Subtype analyses were based on estrogen receptor (ER) status of the first BC. Combined PTVs and pathogenic/likely pathogenic MSVs in BRCA1, BRCA2, and TP53 and PTVs in CHEK2 and PALB2 were associated with increased CBC risk [HRs (95% CIs): 2.88 (1.70-4.87), 2.31 (1.39-3.85), 8.29 (2.53-27.21), 2.25 (1.55-3.27), and 2.67 (1.33-5.35), respectively]. The strongest evidence of association with BCSS was for PTVs and pathogenic/likely pathogenic MSVs in BRCA2 (ER-positive BC) and TP53 and PTVs in CHEK2 [HRs (95% CIs): 1.53 (1.13-2.07), 2.08 (0.95-4.57), and 1.39 (1.13-1.72), respectively, after adjusting for tumor characteristics and treatment]. HRs were essentially unchanged when censoring for CBC, suggesting that these associations are not completely explained by increased CBC risk, tumor characteristics, or treatment. There was limited evidence of associations of PTVs and/or rare MSVs with CBC risk or BCSS for the 25 suspected BC genes. The CBC findings are relevant to treatment decisions, follow-up, and screening after BC diagnosis.
AB - Evidence linking coding germline variants in breast cancer (BC)-susceptibility genes other than BRCA1, BRCA2, and CHEK2 with contralateral breast cancer (CBC) risk and breast cancer-specific survival (BCSS) is scarce. The aim of this study was to assess the association of protein-truncating variants (PTVs) and rare missense variants (MSVs) in nine known (ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53) and 25 suspected BC-susceptibility genes with CBC risk and BCSS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox regression models. Analyses included 34,401 women of European ancestry diagnosed with BC, including 676 CBCs and 3,449 BC deaths; the median follow-up was 10.9 years. Subtype analyses were based on estrogen receptor (ER) status of the first BC. Combined PTVs and pathogenic/likely pathogenic MSVs in BRCA1, BRCA2, and TP53 and PTVs in CHEK2 and PALB2 were associated with increased CBC risk [HRs (95% CIs): 2.88 (1.70-4.87), 2.31 (1.39-3.85), 8.29 (2.53-27.21), 2.25 (1.55-3.27), and 2.67 (1.33-5.35), respectively]. The strongest evidence of association with BCSS was for PTVs and pathogenic/likely pathogenic MSVs in BRCA2 (ER-positive BC) and TP53 and PTVs in CHEK2 [HRs (95% CIs): 1.53 (1.13-2.07), 2.08 (0.95-4.57), and 1.39 (1.13-1.72), respectively, after adjusting for tumor characteristics and treatment]. HRs were essentially unchanged when censoring for CBC, suggesting that these associations are not completely explained by increased CBC risk, tumor characteristics, or treatment. There was limited evidence of associations of PTVs and/or rare MSVs with CBC risk or BCSS for the 25 suspected BC genes. The CBC findings are relevant to treatment decisions, follow-up, and screening after BC diagnosis.
U2 - 10.1016/j.ajhg.2023.02.003
DO - 10.1016/j.ajhg.2023.02.003
M3 - SCORING: Journal article
C2 - 36827971
VL - 110
SP - 475
EP - 486
JO - AM J HUM GENET
JF - AM J HUM GENET
SN - 0002-9297
IS - 3
ER -